Taiyen Biotech Co. Ltd.

Taiyen Biotech Co. Ltd.

TTWSE:1737
30.15
TWD
+0.05
(+0.17%)
1.94EPS
16.38P/E
6.38BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.73
12.99
13.81
13.78
13.79
15.01
14.53
15.65
20.48
18.07
17.04
16.19
16.54
15.95
Basic EPS, GAAP
0.46
1.07
1.34
1.76
1.77
2.26
1.73
1.83
1.97
2.13
1.5
1.86
2
1.95
Free Cash Flow per Basic Share
0.4
1.11
1.39
1.89
1.19
0.79
0.22
0.36
1.05
1.67
0.55
1.76
0.65
1.22
Dividend per Share
0.26
0.5
1
1.12
1.5
1.5
1.8
1.5
1.35
1.5
1.5
1.2
1.3
- -
Book Value per Share
28.67
29.12
29.31
29.93
30.09
30.78
30.76
31.15
31.81
32.61
32.46
33.32
34.07
33.55
Tangible Book Value per Share
28.57
29.03
29.25
29.9
30.07
30.76
30.74
31.11
31.76
32.58
32.42
33.26
34.02
33.49
Basic Weighted Avg Shares
276
200
200
200
200
200
200
200
200
200
200
200
200
200
Sales/Revenue/Turnover
2,409
2,597
2,761
2,755
2,757
3,001
2,907
3,130
4,096
3,614
3,409
3,238
3,308
3,190
Operating Margin (%)
4.26
6.35
11.2
14.87
15.16
13.94
14.44
14.8
12.92
12.32
11.59
13.3
14.1
12.4
Depreciation Expense
132
139
159
167
162
170
171
186
190
195
198
219
246
258
Net Income, GAAP
126
214
269
352
354
453
346
365
393
427
300
372
400
390
Effective Tax Rate (%)
12.25
12.73
15.79
15.15
17.07
14.83
19.38
19.28
19.17
19.43
33.98
26.69
20.3
18.89
Profit Margin (%)
5.23
8.26
9.74
12.77
12.83
15.08
11.89
11.66
9.6
11.81
8.81
11.47
12.09
12.21
Working Capital
1,681
1,783
1,916
2,268
2,142
2,237
1,964
2,206
2,089
2,168
1,925
1,762
1,796
1,715
LT Debt
- -
- -
- -
- -
- -
- -
109
158
89
98
98
31
27
24
Total Equity
5,735
5,825
5,861
5,986
6,019
6,156
6,153
6,364
6,513
6,662
6,549
6,668
6,814
6,709
Return on Invested Capital (%)
1.46
2.46
4.39
5.77
5.63
5.72
5.27
5.63
6.2
5.1
2.98
3.73
5.38
5
Return on Capital (%)
2.04
3.67
4.55
5.88
5.79
7.31
5.44
5.43
5.54
6.16
5.59
6.22
5.83
5.69
Return on Common Equity (%)
2.06
3.71
4.6
5.94
5.89
7.44
5.61
5.9
6.25
6.62
4.62
5.65
5.93
5.87

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
197
178
204
LT Borrowings
- -
- -
- -
LT Finance Leases
27
25
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
200
200
200
Market Capitalization
6,340
6,340
6,380

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,756
2,822
2,877
Cash, Cash Equivalents & STI
1,746
1,815
1,966
Accounts Receivable, Net
198
137
104
Inventories
377
415
366
Total Current Liabilities
960
868
1,162
Payables & Accruals
- -
- -
- -
ST Debt
197
178
204
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.53%
1.38%
2.19%
Free Cash Flow
29.9%
68.88%
-63.05%
Net Income, GAAP
5.93%
3.59%
7.63%
Sales/Revenue/Turnover
2.38%
2.11%
2.15%
Total Cash Common Dividend
- -
- -
8.33%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
813
804
839
782
3,238
2025
819
857
815
816
3,308
2026
790
769
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.52
0.5
0.45
0.38
1.86
2025
0.49
0.44
0.36
0.72
2
2026
0.47
0.4
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.2
2025
- -
- -
- -
- -
1.3
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shih Hui Chen
Full Time Employees
479
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
No. 297, Chien-Kang Road Tainan TQ Taiwan 702
IPO Date
Nov 18, 2003
Business
Taiyen Biotech Co., Ltd. is a biotechnology company primarily engaged in the production and sale of monosodium glutamate (MSG), nucleotides, natural flavor enhancers, seasoning blends, and functional food ingredients. The company’s product portfolio includes high-quality MSG; 5’-ribonucleotides such as disodium inosinate (IMP) and disodium guanylate (GMP); natural flavor enhancers derived from yeast extracts; specialty seasonings; health supplements; and bioactive compounds. Taiyen Biotech serves food manufacturers, seasoning producers, and health-conscious consumers, operating predominantly in Taiwan with international distribution networks across Asia and other regions. Founded in 1962 and headquartered in Taiwan, the company has expanded its biotechnology capabilities into fermentation technologies and sustainable natural ingredients. In recent developments within the last one to two years, Taiyen Biotech has pursued strategic business expansions through partnerships and product innovation aimed at enhancing its market position in functional food and health supplements. The company has introduced several new lines of bioactive peptides and plant-based functional ingredients targeting health and wellness markets. Furthermore, Taiyen Biotech has strengthened its supply chain and manufacturing efficiency by adopting advanced biotechnology processes and equipment modernization. These initiatives underscore its strategic shift towards higher value-added biotech applications and sustainable production methods while maintaining its core focus on seasoning and food ingredient products. Taiyen Biotech operates in the biotechnology and food ingredient industry segments, with key customer bases including food processors, nutraceutical companies, and health supplement distributors. It leverages proprietary fermentation technologies and extensive research and development to customize ingredients for specific applications in flavor enhancement and health promotion. The company maintains a robust market presence in Taiwan and exports to markets in East Asia, Southeast Asia, and beyond. Taiyen Biotech is publicly listed on the Taiwan Stock Exchange under the ticker 1737.TW. This description integrates Taiyen Biotech’s comprehensive lineup of food ingredient products and its recent major strategic moves in product development and operational improvements, reflecting its status as a leading biotechnology and specialty seasoning provider headquartered in Taiwan.